BTC Capital Management Inc. Buys 2,044 Shares of Danaher Corporation $DHR

Key Points

• BTC Capital Management Inc. has increased its stake in Danaher Corporation by 7.9%, now owning 28,037 shares valued at approximately $5.53 million.
• Danaher recently reported $1.80 EPS for the quarter, exceeding analysts' expectations, with revenues of $5.94 billion, an increase of 3.4% year-over-year.
• The company has declared a quarterly dividend of $0.32 per share, set to be paid on October 31st, reflecting an annualized dividend yield of 0.7%.

BTC Capital Management Inc. lifted its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 7.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 28,037 shares of the conglomerate's stock after purchasing an additional 2,044 shares during the quarter. BTC Capital Management Inc.'s holdings in Danaher were worth $5,529,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in DHR. GHP Investment Advisors Inc. increased its holdings in shares of Danaher by 396.0% in the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after purchasing an additional 99 shares during the last quarter. Heck Capital Advisors LLC bought a new stake in Danaher during the fourth quarter worth about $27,000. Sierra Ocean LLC lifted its position in Danaher by 116.9% during the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock worth $29,000 after purchasing an additional 76 shares during the period. Smallwood Wealth Investment Management LLC bought a new position in shares of Danaher in the first quarter worth about $31,000. Finally, Dunhill Financial LLC lifted its holdings in shares of Danaher by 68.4% in the first quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock worth $34,000 after acquiring an additional 67 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Price Performance

Shares of NYSE DHR traded down $1.54 during midday trading on Tuesday, hitting $188.92. 1,439,592 shares of the company's stock were exchanged, compared to its average volume of 4,129,451. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $279.90. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The company has a market cap of $135.28 billion, a price-to-earnings ratio of 40.20, a PEG ratio of 2.70 and a beta of 0.75. The business's fifty day moving average price is $200.02 and its two-hundred day moving average price is $198.03.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.16. The business had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.Danaher's revenue for the quarter was up 3.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, research analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Friday, September 26th. Danaher's dividend payout ratio is currently 27.23%.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on DHR. Robert W. Baird raised their price objective on shares of Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a report on Friday, July 18th. Evercore ISI dropped their price objective on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Guggenheim reiterated a "buy" rating and issued a $250.00 price objective on shares of Danaher in a report on Wednesday, July 23rd. Scotiabank upgraded shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective for the company in a report on Friday, July 11th. Finally, Bank of America dropped their price objective on shares of Danaher from $230.00 to $220.00 and set a "buy" rating for the company in a report on Monday. Seventeen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, Danaher currently has a consensus rating of "Moderate Buy" and an average price target of $245.91.

Insider Activity at Danaher

In related news, Director Teri List sold 2,778 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director owned 20,751 shares in the company, valued at $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 11.20% of the stock is currently owned by corporate insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.